Kenneth Aldape

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Disclosure: NO DISCLOSURE INFORMATION SUBMITTED

Presentation(s):

• Editor-in-Chief, Neuro-Oncology

  Friday, November 22
  12:15 PM – 12:35 PM

• CMET-32 - DNA methylation alterations in lung adenocarcinomas that develop brain metastases

  Friday, November 22
  3:35 PM – 3:45 PM

• Concurrent Session 2B: Discussant

  Friday, November 22
  4:25 PM – 4:35 PM

• PATH-20 - Investigation of clinically aggressive spinal cord ependymoma through methylation analysis

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-21 - A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM)

  Saturday, November 23
  11:50 AM – 12:00 PM

• CMET-30 - Comprehensive methylome analysis of EGFR-mutant primary lung adenocarcinoma and matched brain metastasis

  Saturday, November 23
  2:50 PM – 2:55 PM

• PATH-21 - Clinical utility of DNA methylation profiling for diagnosis of challenging central nervous system tumors: The Toronto experience

  Saturday, November 23
  5:00 PM – 7:00 PM

• EPID-31 - Efficient study of surgically treated meningioma through clinical data standardization

  Saturday, November 23
  5:00 PM – 7:00 PM

• RBTT-11 - NRG Oncology NRG-BN006: A phase II/III randomized, open-label study of Toca 511 and Toca FC with standard of care compared to standard of care in patients with newly diagnosed glioblastoma

  Saturday, November 23
  5:00 PM – 7:00 PM

• Neuropathology Implications of Molecular Classification and Grading in IDH Mutant Gliomas

  Sunday, November 24
  7:30 AM – 8:00 AM